Associate Professor Michael Hill
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Associate Professor Mike Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Mike works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2005; No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke.
Holmes MV. et al, (2018), J Am Coll Cardiol, 71, 620 - 632
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Parish S. et al, (2018), Circ Genom Precis Med, 11
Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults
Millwood IY. et al, (2018), JAMA CARDIOLOGY, 3, 34 - 43
Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults.
Millwood IY. et al, (2018), JAMA Cardiol, 3, 34 - 43
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group None., (2017), Nephrol Dial Transplant, 32, 2043 - 2051